Roh, Michelle E., Unger, Holger and Oldenburg, Catherine (2025) 'Revisiting Azithromycin for Intermittent Preventive Treatment in Pregnancy'. The American Journal of Tropical Medicine and Hygiene. (In Press)
![]() |
Text
tpmd-article-10.4269-ajtmh.24-0734.pdf - Accepted Version Available under License Creative Commons Attribution. Download (546kB) |
Abstract
In malaria-endemic regions of Africa, the World Health
Organization recommends pregnant women receive inter�mittent preventive treatment in pregnancy (IPTp), which
entails providing full treatment courses of a long-acting anti�malarial from the second trimester to delivery, with doses
given at least one month apart.1 Sulfadoxine-pyrimethamine
(SP) is the only antimalarial currently recommended for IPTp,
but its antimalarial efficacy is threatened by the emergence
and spread of SP resistance. Azithromycin (AZ) has been
considered as a potential partner drug for IPTp, with the aim
of strengthening antimalarial protection while also impacting
on other factors associated with adverse birth outcomes.
Several clinical trials of AZ-containing IPTp regimens have
been conducted, including combinations of AZ with SP,2-5
chloroquine,6 dihydroartemisinin-piperaquine (DP),7 pipera�quine,8 and trimethroprim-sulfamethoxazole
Item Type: | Article |
---|---|
Subjects: | WB Practice of Medicine > WB 102.5 Clinical medicine - evidence-based practice WQ Obstetrics > Pregnancy Complications > WQ 240 Pregnancy complications (General) |
Faculty: Department: | Clinical Sciences & International Health > Clinical Sciences Department |
Digital Object Identifer (DOI): | https://doi.org/10.4269/ajtmh.24-0734 |
SWORD Depositor: | JISC Pubrouter |
Depositing User: | JISC Pubrouter |
Date Deposited: | 12 Mar 2025 13:11 |
Last Modified: | 12 Mar 2025 13:11 |
URI: | https://archive.lstmed.ac.uk/id/eprint/26176 |
Statistics
Actions (login required)
![]() |
Edit Item |